Document:

Exhibit
10.6

 

	Inhibikase Therapeutics, Inc.
	Employment Agreement
	Milton H. Werner, Ph.D.

 

EMPLOYMENT
AGREEMENT

 

THIS EMPLOYMENT
AGREEMENT (the “Agreement”), dated as of April 1, 2014 (the “Effective Date”) is entered into by and
between Milton H. Werner, Ph.D., an individual currently residing at 874 Birds ML SE, Marietta, Georgia, 30067 (“Executive”),
and Inhibikase Therapeutics, Inc., a Delaware corporation, with its principal place of business located at 3350 Riverwood Parkway,
Suite 1900, Atlanta, Georgia 30339 (the “Company”). Except as otherwise defined herein, capitalized terms and phrases
shall have the meaning ascribed thereto in Section 14 of this Agreement.

 

WHEREAS, the
Company and Executive desire to set forth the terms and conditions under which Executive shall be employed, and upon which Executive
shall be compensated by the Company.

 

WHEREAS, the
Company desires to continue to employ Executive as its President and Chief Executive Officer for the period and upon the terms
and conditions set forth in this Agreement.

 

WHEREAS, Executive
desires to serve in such capacities for such period and upon such terms.

 

NOW THEREFORE,
in consideration of the foregoing recitals, the mutual promises and agreements hereinafter set forth, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Executive agree as follows:

 

		1.	Term. The Company agrees to employ Executive, and Executive accepts such employment with
the Company, upon the terms and subject to the conditions set forth in this Agreement. Executive’s employment shall commence
as of the Effective Date and shall continue until terminated in accordance with this Agreement (the “Term”).

 

		2.	Title; Duties; Board Membership; Principal Place of Employment.

 

		a.	Title; Duties. During the Term, Executive shall serve as the President and Chief Executive
Officer of the Company, reporting directly to the Board. Executive shall perform such specific duties as are commensurate with
such positions and such other duties as may be assigned to Executive from time to time by the Board.

 

		b.	Board Membership. Executive will continue to serve as a member of the Board; provided,
however, that Executive’s continued service as a member of the Board will be subject to any required stockholder approval.

 

    

    	Inhibikase Therapeutics, Inc.
	Employment Agreement
	Milton H. Werner, Ph.D.

    

 

		c.	Principal Place of Employment. Executive’s principal place of employment shall be
Atlanta, Georgia. In the event the Company relocates its headquarters, with Board approval, by more than twenty-five miles from
its location as of the Effective Date, the Company shall reimburse Executive for the following expenses to the extent such expenses
are incurred by Executive within six (6) months of the date of the relocation (collectively, the “Relocation Expenses”):

 

		(A)	House Hunting. Out-of-pocket expenses (including house hunting trips, travel, seven (7) days hotel,
car rental and meals) reasonably and actually incurred by him and his spouse for relocation from his current residence to the new
location, in an amount not to exceed Ten Thousand Dollars ($10,000), fifty percent (50%) of which shall be paid by Company to Executive
within thirty (30) days of Company’s receipt of supporting substantiation (the “Substantiation Date”) and the
balance being paid within ninety (90) days following the date on which Executive completes his relocation (the “House Hunting
Expenses”);

 

		(B)	Interim Living Expenses. Three (3) months of lodging, meals and car rental for himself and his
spouse in connection with such relocation (the “Interim Lodging Expenses”); provided, however, that Executive
shall obtain prior written consent from Company prior to incurring all such expenses incurred in connection with lodging; provided,
further, that Company shall not reimburse Executive for any such lodging expenses incurred by Executive following the date
on which Executive moves into his primary residence; and

 

		(C)	Return Visits. Four (4) round trip coach airline tickets; provided, however, that such tickets
must be used by Executive within three (3) months of the office relocation; provided, further, that in the event Executive
does not use the four (4) airline tickets within the time period set forth in this Section, a reasonable amount reflecting the
cost of such unused airline tickets may be applied by Executive to other Relocation Expenses.

 

		3.	Outside Activities. Executive shall serve the Company faithfully and to the best of his
ability, shall use his business judgment, skill and best efforts to the advancement of the interests of the Company during the
Term. Notwithstanding the foregoing, Executive may engage in other activities, such as outside consulting work, activities involving
charitable, educational, religious, trade association, civic and similar types of organizations, speaking engagements and membership
on the Board of Directors or equivalent of other organizations (collectively, “Outside Activities”), provided, however,
that Executive’s participation in such Outside Activities is disclosed in writing and in advance to the Board of Directors
or any designated committee thereof, consistent with applicable laws and Company policy and does not conflict with Executive’s
obligations under this Agreement, and provided further that if the Company determines in good faith that any Outside Activity is
inconsistent with applicable law or the Company policy, or conflicts with Executive’s obligations under this Agreement, Executive
will cease any such Outside Activity upon written notice from the Company’s Board of Directors.

 

		4.	Cash Compensation.

 

		a.	Base Salary. During the Term of this Agreement, Executive shall receive a base salary (the
 “Base Salary”) at a gross rate of $18,666.66 per month ($224,000 per annum), payable in substantially equal installments
in accordance with the Company’s normal payroll practices for payment of its employees, as in effect from time to time. Executive’s
Base Salary shall be subject to adjustment from time to time, as determined by the Company’s Board of Directors in its sole
discretion.

 

    -2- 

    	Inhibikase Therapeutics, Inc.
	Employment Agreement
	Milton H. Werner, Ph.D.

    

 

		b.	Bonuses or Other Compensation. During the Term of this Agreement, the Company’s Board
of Directors, in its sole discretion, may award additional compensation to Executive other than as specifically provided by this
Agreement, in either or both monetary or non-monetary forms.

 

		5.	Equity Compensation.

 

		a.	Initial Stock Option Grants. In connection with Executive serving as President and Chief
Executive Officer of the Company, Executive was granted the fully-vested option to purchase Fifty Thousand (50,000) shares of Company
common stock pursuant to that certain nonqualified stock option agreement entered into by and between Company and Executive as
of the 1st day of June 2011 (the “2011 Stock Option Agreement”) and Company’s 2011 Equity Incentive
Plan (the “Plan”).

 

		b.	Annual Stock Option Grants.For so long as Executive remains employed by the Company,
on each anniversary of the Effective Date, Company hereby agrees to grant and Executive hereby agrees to accept as of such anniversary
(the “Grant Date”) an unvested, nonqualified option to purchase Twenty-Five Thousand (25,000) shares of Company common
stock with a per share exercise price equal to the fair market value as of each such share as determined on the Grant Date (the
 “Annual Option Grant”). Absent separate agreement between Executive and the Company’s Board of Directors, all
such annual grants will cease as of the termination of Executive’s employment with the Company. Each respective Annual Option
Grant shall be subject to a vesting schedule such that Executive’s right to exercise such options shall vest pro rata
over the ensuing twelve (12) consecutive calendar month period beginning with the Grant Date, with each such pro rata portion
thereof continuing to vest so long as Executive remains employed under the terms of this Agreement with Company on the last day
of each such monthly period. Except for the Grant Date and exercise price, the Annual Option Grant shall be subject to the same
terms and conditions as the 201_ Stock Option Agreement and otherwise subject to the terms and conditions of the Plan or any successor
incentive equity plan thereof.

 

		c.	Additional Stock Option Grants. In its sole discretion, the Company may grant to Executive
from time to time other stock options to purchase additional shares of Company common stock, also pursuant to the Plan and such
other terms and conditions set forth at the time of such grant (the “Additional Option Grants,” and together with the
 “Initial Option Grants” and “Annual Option Grants,” the “Option Grants”) and may also grant
other forms of equity as permitted by the Plan.

 

		d.	Change of Control. In the event the Company undergoes a Change of Control (as defined herein),
100% of the then-unvested right to purchase shares of Company common stock under the then in effect Option Grants shall vest in
full and the option grants thereunder shall be fully exercisable, subject, however, to all other terms and conditions thereof remaining
in full force and effect.

 

    -3- 

    	Inhibikase Therapeutics, Inc.
	Employment Agreement
	Milton H. Werner, Ph.D.

    

 

		6.	Executive Benefits.

 

		a.	Generally. During the Term of this Agreement, Executive shall be eligible to participate
in all benefit and fringe benefit plans made available to other executive officers of the Company. Any such participation shall
be subject to the terms and conditions of the applicable plan documents, applicable law, generally applicable Company policies,
and the discretion of the Company, all as provided for in or contemplated by such plans. Subject to the terms of such plans and
applicable law, the Company may alter, modify, add to or delete its employee benefit plans at any time, in its sole discretion,
without recourse by Executive.

 

		b.	Vacation. Executive shall be entitled to three (3) weeks per year paid vacation time as
provided in the Company’s vacation policies and procedures as in effect from time to time. Executive may take accrued vacation
at such time or times as are mutually agreed upon by Executive and the Company. All matters relating to vacation time, including
but not limited to accrual, carryover and forfeiture of vacation time, shall be governed by, and Executive agrees to be bound by,
the Company’s policies and procedures regarding vacation time as in effect from time to time.

 

		c.	Executive Discretionary Expenditures. Upon the Effective Date and throughout the duration
of Executive’s employment with the Company, the Company shall reimburse to Executive for executive discretionary expenditures,
including, but not limited to, life insurance (with Executive naming a personally selected beneficiary), car lease, country club
memberships, etc., up to a maximum of thirteen thousand dollars ($13,000) annually. Such reimbursements shall be made within ten
(10) calendar days of the date on which each is presented with a statement for payment.

 

		7.	Expenses. The Company will reimburse Executive for reasonable travel, entertainment and
other expenses incurred by Executive in the furtherance of the performance of Executive’s duties hereunder, in accordance
with the Company’s expense reimbursement policy as in effect from time to time. The Company and/or its Board of Directors,
in its discretion, may periodically audit or review such expenses to ensure they are for legitimate business expenses.

 

		8.	Deduction and Withholding. Notwithstanding any other provision of this Agreement, any payments
or benefits hereunder shall be subject to the withholding of such amounts, if any, relating to tax and other payroll deductions,
as the Company reasonably determines it should withhold pursuant to any applicable law or regulation.

 

    -4- 

    	Inhibikase Therapeutics, Inc.
	Employment Agreement
	Milton H. Werner, Ph.D.

    

 

		9.	Termination of Agreement.

 

		a.	Termination Date. Executive’s employment and this Agreement (except as otherwise provided
hereunder) shall terminate upon the first to occur of (i) any of the following, at the time set forth therefore (the “Termination
Date”):

 

		i.	Mutual Termination. At any time by the mutual written agreement of Company and Executive;

 

		ii.	Death or Disability. Immediately upon the death of Executive or, subject to applicable law, if
any, a determination by Company that Executive is or has become Disabled;

 

		iii.	Voluntary Termination By Executive. Four (4) weeks following Executive’s written notice to
Company of termination of employment; provided, however, that Company may waive all or a portion of such notice period and
accelerate the effective date of such termination (termination pursuant to this Subsection being referred to herein as “Voluntary”
termination);

 

		iv.	Termination For Cause By Company. Immediately following notice of termination for “Cause”
given by Company (as defined below) and failure by Executive to Cure (as defined below), if applicable, with such notice specifying
such Cause (termination pursuant to this Subsection being referred to herein as termination for “Cause”);

 

		v.	Termination Without Cause By Company. Notwithstanding any other provision in this Agreement to
the contrary, including, but not limited to Section 1 above, Company may terminate without Cause Executive’s employment under
this Agreement on four (4) weeks’ notice (termination pursuant to this Subsection being referred to herein as termination
 “Without Cause”); or

 

		vi.	Termination For Good Reason by Executive. Subject to the notice and remedy provisions described
in Section 14(d) below, at the election of Executive for Good Reason so long as the Separation From Service (as such phrase is
defined in Internal Revenue Code of 1986, as amended (the “Code”) Section 409A; Treasury Regulations Section 1.409A-1(h))
on account of any such condition occurs not later than sixty (60) days following the expiration of the thirty-day (30-day) remedy
period described in Section 14(d) below ;

 

		b.	No limitation on Remedies. Termination pursuant to this Section 9 shall be in addition to and without
prejudice to any other right or remedy to which Company may be entitled at law, in equity, or under this Agreement.

 

		10.	Basics Rights at Termination. In the event Executive’s employment with the Company
is terminated for any reason, Executive will be entitled to any (a) unpaid Base Salary accrued up to the effective date of termination;
(b) benefits or compensation as provided under the terms of any employee benefit and compensation agreements or plans applicable
to Executive; (c) unreimbursed business expenses required to be reimbursed to Executive in accordance with and subject to Company’s
policies applicable thereto; and (d) rights of indemnification to which Executive may be entitled as of the Termination Date under
the Company’s Articles of Incorporation, Bylaws, this Agreement, or separate indemnification agreement, as applicable. In
addition, if the termination is by the Company without Cause or Executive resigns for Good Reason, Executive will be entitled to
amounts and benefits specified in Section 11(b) of this Agreement.

 

    -5- 

    	Inhibikase Therapeutics, Inc.
	Employment Agreement
	Milton H. Werner, Ph.D.

    

 

		11.	Severance.

 

		a.	Termination Without Cause or Resignation for Good Reason other than in Connection with a Change
of Control. If Executive’s employment is terminated by the Company without Cause or if Executive resigns for Good Reason,
and such termination is not in Connection with a Change of Control, then, subject to Section 10(d), Executive will receive: (i)
continued payment of the of Executive’s Base Salary as is in effect on the Termination Date (less applicable tax withholdings)
for that six (6) consecutive calendar month period thereafter, such amounts to be paid out monthly in accordance with the Company’s
normal payroll policies; (ii) six (6) months accelerated vesting with respect to Executive’s then outstanding, unvested equity
awards; (iii) extension of the exercise period for all Executive’s outstanding stock options to the latter of 165 calendar
days from the date of termination or the expiration date of the stock options; (iv) reimbursement for premiums paid for continued
health benefits for Executive (and any eligible dependents) under the Company’s health plans until the earlier of (x) six
(6) months, payable when such premiums are due (provided Executive validly elects to continue coverage under the Consolidated Omnibus
Budget Reconciliation Act (“COBRA”) or similar state law or (y) the date upon which Executive and Executive’s
eligible dependents become covered under similar plans; and (v) assignment by Company of the life insurance as set forth in Section
6(c). The Executive agrees that such payments could be delayed if the Company’s capitalization at the time of termination
is less than $3,000,000.

 

		b.	Termination Without Cause or Resignation for Good Reason in Connection with a Change of Control.
If Executive’s employment is terminated by the Company without Cause or by Executive for Good Reason, and the termination
is in Connection with a Change of Control, then, subject to Section 10(d), Executive will receive: (i) continued payment of twelve
(12) month’s Base Salary, less applicable tax withholdings, in accordance with the Company’s normal payroll policies;
(ii) full vesting with respect to Executive’s then outstanding unvested equity awards; (iii) extension of the exercise period
for all Executive’s outstanding stock options to the latter of 165 calendar days from the date of termination or the expiration
date of the stock options; (iv) reimbursement for premiums paid for continued health benefits for Executive (and any eligible dependents)
under the Company’s health plans until the earlier of (x) twelve (12) months, payable when such premiums are due (provided
Executive validly elects to continue coverage under COBRA or similar state law), or (y) the date upon which Executive and Executive’s
eligible dependents become covered under similar plans; and (v) assignment by Company of the life insurance as set forth in Section
6(c). The Executive agrees that such payments could be delayed if the Company’s capitalization at the time of termination
is less than $5,000,000.

 

    -6- 

    	Inhibikase Therapeutics, Inc.
	Employment Agreement
	Milton H. Werner, Ph.D.

    

 

		c.	Voluntary Termination Without Good Reason or Termination for Cause. If Executive’s
employment is terminated voluntarily by him, including due to his death or Disability, without Good Reason or is terminated for
Cause by the Company, then, except as otherwise provided in the first sentence of Section 10 above, (1) all further vesting of
Executive’s outstanding equity awards will terminate immediately; and (ii) all payments of compensation by the Company to
Executive hereunder will terminate immediately.

 

		d.	Separation Agreement and Release of Claims. The receipt of any severance or other benefits
pursuant to this Section 11 will be subject to and conditioned on Executive first signing and not otherwise revoking a separation
agreement and release of claims in substantially the form appended hereto as Exhibit A (the “Release Agreement”). For
this purpose, the Release Agreement must be signed by Executive and returned to the Company no later than thirty (30) days following
the Termination Date in accordance with the terms of the Release Agreement. Notwithstanding any other provision of this Agreement
to the contrary, no severance or other benefits will be paid or provided unless the Release Agreement becomes effective, and any
severance amounts or benefits otherwise payable between the date the Termination Date and the forty-fifth (45th) day following
the Termination Date will be paid on such forty-fifth (45th) day.

 

		e.	No Duty to Mitigate. Executive will not be required to mitigate the amount of any payment
contemplated by this Agreement, nor will any earnings that Executive may receive from any other source reduce any such payment.

 

		12.	Excise Tax Gross-Up. In the event that the benefits provided for in this Agreement constitute
 “parachute payments” within the meaning of Section 280G of the Code and will be subject to the excise tax imposed by
Section 4999 of the Code, then Executive will receive (i) a payment from the Company sufficient to pay such excise tax, and (ii)
an additional payment from the Company sufficient to pay the federal and state income and employment taxes and additional excise
taxes arising from the payments made to Executive by the Company pursuant to this sentence. However, the Company may elect not
to make payments under the preceding sentence to the extent it reasonably determines that (a) the “parachute payments”
arise from the acceleration of options with exercise prices exceeding the price at which the underlying shares could be sold on
the date of the Change in Control and (b) any payments under the preceding sentence would not significantly benefit the Executive.
Unless Executive and the Company agree otherwise in writing, the determination of Executive’s excise tax liability, if any,
and the amount, if any, required to be paid under this Section 12 will be made in writing by a certified public accounting firm
selected by the Company and reasonably acceptable to the Executive (the “Accountants”). For purposes of making the
calculations required by this Section 12, the Accountants may make reasonable assumptions and approximations concerning applicable
taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code.
Executive and the Company agree to furnish such information and documents as the Accountants may reasonably request in order to
make a determination under this Section 12. The Company will bear all costs the Accountants may reasonably incur in connection
with any calculations contemplated by this Section 12. Any payment to Executive under this Section 12 shall be made within thirty
(30) days following receipt by the Company of the report of the Accountants setting forth such determination, but in no event later
than March 30 of the calendar year following the calendar year in which Executive’s employment is terminated.

 

    -7- 

    	Inhibikase Therapeutics, Inc.
	Employment Agreement
	Milton H. Werner, Ph.D.

    

 

		13.	Deferral of Payments in excess of Code Section 162(m) Limitation. Notwithstanding any provision
of this Agreement or any other agreement entered into by and between Company and Executive, Company may further elect to delay
the payment of any Section 162(m) Excess Compensation until (a) the Executive’s first taxable year in which Company reasonably
anticipates or should reasonably anticipate if payment is made during such year, the deduction would not be barred by the application
of Section 162(m) or (b) during the period beginning with the date of the Executive Separation From Service and ending on the later
of the last day of the taxable year of Company in which Executive separates from service or the 15th day of the third
month following the Executive’s Separation From Service; provided, further, that where any scheduled payment to Executive
in Company’s taxable year is delayed in accordance with this paragraph, the delay in payment will be treated as a subsequent
deferral election unless all scheduled payments to that Executive that could be delayed in accordance with this paragraph are also
delayed. Where the payment is delayed to a date on or after Executive’s Separation From Service, the payment will be considered
a payment upon a Separation From Service for purposes of the rules under Section 1.409A-3(i)(2) (payments to specified employees
upon a Separation From Service) and, in the case of a specified employee, the date that is six months after Executive’ Separation
From Service is substituted for any reference to Executive’s Separation From Service in the first sentence of this paragraph.
For purposes of this Agreement, the phrase “Section 162(m) Excess Compensation” shall mean that amount payable under
this Agreement (when aggregated with all other payments paid or to be paid by Executive and which are covered by Code Section 162(m))
to the extent Company reasonably anticipates that if paid as scheduled, Company’s deduction with respect to such payment
would not be permitted due to the application of Code Section 162(m).

 

		14.	Definitions.

 

		a.	Cause. For purposes of this Agreement, “Cause” will mean:

 

		i.	Executive’s willful and continued failure to perform the duties and responsibilities of his
position after there has been delivered to Executive a written demand for performance from the Board which describes in reasonable
detail the basis for the Board’s belief that Executive has not substantially performed his duties and provides Executive
the opportunity to present to the Board his good faith reasons for not so performing and, if the Board does not agree with such
reasons, with thirty (30) days to take corrective action;

 

		ii.	Executive’s conviction of, or plea of nolo contendere to, a felony;

 

		iii.	A breach of any fiduciary duty owed to the Company by Executive;

 

    -8- 

    	Inhibikase Therapeutics, Inc.
	Employment Agreement
	Milton H. Werner, Ph.D.

    

 

		iv.	Executive being found individually liable in any Securities and Exchange

 

Commission or other civil or
criminal securities law action or entering any cease and desist order with respect to such action (regardless of whether or not
Executive admits or denies liability);

 

		v.	Executive (A) obstructing or impeding; (B) endeavoring to influence, obstruct or impede, or (C)
failing to materially cooperate with, any investigation authorized by the Board or any governmental or self-regulatory entity (an
 “Investigation”). However, Executive’s failure to waive attorney-client privilege relating to communications
with Executive’s own attorney in connection with an Investigation will not constitute “Cause”; or

 

		vi.	Executive’s disqualification or bar by any U.S, governmental or self-regulatory authority
from serving in the capacity contemplated by this Agreement or Executive’s loss of any U.S. governmental or self-regulatory
license that is reasonably necessary for Executive to perform his responsibilities to the Company under this Agreement, if (A)
the disqualification, bar or loss continues for more than thirty (30) days, and (B) during that period the Company uses its good
faith efforts to cause the disqualification or bar to be lifted or the license replaced. While any disqualification, bar or loss
continues during Executive’s employment, Executive will serve in the capacity contemplated by this Agreement to whatever
extent legally permissible and, if Executive’s employment is not permissible, Executive will be placed on leave (which will
be paid to the extent legally permissible).

 

		b.	Change in Control. For purposes of this Agreement, “Change in Control” will
mean any change in the ownership, change in the effective control, or change in the substantial ownership of assets, within the
meaning of those terms in Treasury Regulations Section 1.280G-1, Q&A 27 through and including 29, of the Company.

 

		c.	Change of Control. For purposes of this Agreement, “Change of Control” will
mean the occurrence of any of the following events:

 

		i.	The consummation by the Company of a merger or consolidation of the Company with any other corporation,
other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto
continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity)
more than 50% of the total voting power represented by the voting securities of the Company or such surviving entity outstanding
immediately after such merger or consolidation;

 

		ii.	The approval by the stockholders of the Company, or if stockholder approval is not required, approval
by the Board, of either (1) a plan of complete liquidation of the Company or (2) an agreement for the sale or disposition by the
Company of all or substantially all of the Company’s assets; or

 

    -9- 

    	Inhibikase Therapeutics, Inc.
	Employment Agreement
	Milton H. Werner, Ph.D.

    

 

		iii.	Any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange
Act of 1934, as amended) becoming the “beneficial owner” (as defined in Rule 13d-3 under said Act), directly or indirectly,
of securities of the Company representing 50% or more of the total voting power represented by the Company’s then outstanding
voting securities.

 

		d.	Disability. For purposes of this Agreement, “Disability” will mean Executive’s
inability to substantially perform his duties under this Agreement as a result of incapacity by reason of any medically determinable
physical or mental impairment that can be expected to result in death or to last for a period of twelve (12) months.

 

		e.	Good Reason. For purposes of this Agreement, “Good Reason” means the occurrence
of any of the following conditions, without Executive’s express written consent; provided, however, that Executive’s
employment is terminated no later than one hundred eighty (180) days following the initial existence of one or more of the following
conditions; provided further, that Executive must provide the Company notice of Good Reason within ninety (90) days of the initial
existence of one of the following conditions, upon which notice the Company shall then have thirty (30) days in which to remedy
the condition, under which circumstances the Company shall not be required to pay any amounts specified in Section 11 of this Agreement:

 

		i.	A material diminution in Executive’s authority, duties or responsibilities in effect immediately
prior to such diminution;

 

		ii.	A material diminution in Executive’s Base Salary that persists for longer than 12 months;

 

		iii.	A material diminution in the authority, duties, or responsibilities of the supervisor to whom Executive
is required to report, including a requirement that Executive report to a Company officer or employee instead of reporting directly
to the board of directors of the Company

 

		iv.	A change of more than 75 air miles, measured from the geographic location at which Executive is
to perform his services to the Company on the Effective Date, in the geographic location at which Executive must perform his services
to the Company; or

 

		v.	Any other action or inaction that constitutes a material breach by the Company of this Agreement.

 

		f.	In Connection with a Change of Control. For purposes of this Agreement, a termination by
Company of Executive’s employment with the Company is in Connection with a “Change of Control” if Executive’s
employment is terminated by Company without Cause or by Executive for Good Reason within three (3) months prior or twelve (12)
months following a Change of Control.

 

    -10- 

    	Inhibikase Therapeutics, Inc.
	Employment Agreement
	Milton H. Werner, Ph.D.

    

 

		15.	Indemnification. Subject to applicable law, Executive will be provided indemnification to
the maximum extent permitted by the Company’s Articles of Incorporation, Bylaws, this Agreement, or separate indemnification
agreement, as applicable, including, if applicable, any directors and officers insurance policies, with such indemnification to
be on terms determined by the Board or any of its committees, but on terms no less favorable than provided to any other Company
executive officer or director and subject to the terms of any separate written indemnification agreement.

 

		16.	Section 409A.

 

		a.	Payment of Severance Benefits. The phrase “Executive’s employment is terminated”
and similar or related terms and phrases used in this Agreement shall have the same meaning as or refer to Executive’s experiencing
a “separation from service,” within the meaning of Section 409A of the Code and any final regulations and official
guidance promulgated thereunder (“Section 409A Authority”). Notwithstanding anything to the contrary in this Agreement,
no severance pay or benefits to be paid or provided to Executive, if any, pursuant to this Agreement, when considered together
with any other severance payments or separation benefits that are considered deferred compensation under Section 409A Authority
will be paid or otherwise provided until Executive has a “separation from service” within the meaning of Section 409A
Authority. In addition, if Executive is a “specified employee” within the meaning of Section 409A Authority at the
time Executive’s employment is terminated (other than due to death), then any severance benefits payable to Executive under
this Agreement, and any other severance payments or separation benefits payments that constitute a “deferral of compensation”
under Section 409A Authority (together, the “Deferred Compensation Separation Benefits”) otherwise due to Executive
on or within the six (6) month period following the date Executive’s employment is terminated will accrue during such six
(6) month period and will become payable in a lump sum payment (less applicable withholding taxes) on the date six (6) months and
one (1) day following the date of Executive’s “separation from service.” All subsequent payments, if any, will
be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the
contrary, if Executive dies following the date his employment is terminated but prior to the six (6) month anniversary of that
date, then any payments delayed in accordance with this paragraph will be payable in a lump sum (less applicable withholding taxes)
to Executive’s estate as soon as administratively practicable after the date of Executive’s death and all other Deferred
Compensation Separation Benefits will be payable in accordance with the payment schedule applicable to each payment or benefit.
Each payment of severance benefits to Executive under this Agreement that is made on or before March 14 of the calendar year following
Executive’s employment is terminated and is intended to not constitute a “deferral of compensation” by virtue
of the “short term deferral” rule of Treasury Regulations Section 1.409A-1(b)(4) shall constitute a “separate
payment” for purposes of application of that rule.

 

    -11- 

    	Inhibikase Therapeutics, Inc.
	Employment Agreement
	Milton H. Werner, Ph.D.

    

 

		b.	Amendments to this Agreement with Respect to Section 409A. The severance payments and other
benefits provided under this Agreement are intended to not constitute a “deferral of compensation” under Section 409A
Authority to the extent possible, or, to the extent not so possible, to comply with the requirements of Sections 409A(a)(2),(3)
and (4) of the Code so that none of the severance payments and benefits to be provided hereunder will be subject to the income
inclusion, additional tax or interest provisions of Section 409A(a)(1), and any ambiguities herein will be interpreted in accordance
with that intent The Company and Executive agree to work together in good faith to consider amendments to this Agreement and to
take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or interest
or income recognition prior to actual payment to Executive under Section 409A(a)(1).

 

		c.	Payments. The Company and Executive intend that each installment of payments and benefits
provided under this Agreement shall be treated as a separate identified payment for purposes of Section 409A and that neither the
Company nor Executive shall have the right to accelerate or defer the delivery of any such payments independent of this Agreement
or benefits if a determination is made in good faith that any such acceleration or deferral would present a risk that Executive
would be subject to any tax under Section 409A.

 

		d.	No Guarantee of Tax Consequences. Executive acknowledges and agrees that nothing in this
Agreement shall be construed as a covenant by the Company that no payment will be made or benefit will be provided under this Agreement
which will be subject to taxation under Section 409A or as a guarantee or indemnity by the Company for the tax consequences to
the payments and benefits called for under this Agreement, including any tax consequences under Section 409A. Finally, Executive
agrees that, as between the Company and Executive, Executive shall be responsible for paying all taxes and additions thereto or
thereon due with respect to any and all payments and benefits made under this Agreement.

 

		17.	Notices. Any notice hereunder by either party to the other shall be given in writing by
personal delivery or by registered mail, return receipt requested, addressed, if to the Company, to the attention of the Company’s
Chairman of the Board of Directors at the Company’s principal offices or to such other address as the Company may designate
in writing to Executive, and if to Executive, to his most recent home address on file with the Company. Notice shall be deemed
given, if by personal delivery, on the date of such delivery or, if by registered mail, on the date shown on the applicable return
receipt.

 

		18.	Entire Agreement; Modification.This Agreement constitutes the entire understanding and
agreement between the parties hereto with regard to the subject matter hereof, and supersedes all prior understandings and agreements,
whether written or oral. This Agreement may not be amended, supplemented, revised or otherwise modified except by a writing signed
by the parties hereto.

 

    -12- 

    	Inhibikase Therapeutics, Inc.
	Employment Agreement
	Milton H. Werner, Ph.D.

    

 

		19.	Assignment. This Agreement may not be assigned, in whole or in part, by any party without
the prior written consent of the other party, except that the Company may, without the consent of Executive, assign its rights
and obligations under this Agreement to any corporation, firm or other business entity with or into which the Company may merge
or consolidate, or to which the Company may sell or transfer all or substantially all of its assets. After any such assignment
by the Company, the Company shall be discharged from all further liability hereunder and such assignee shall have all the rights
and obligations of the Company under this Agreement.

 

		20.	Captions, Sections and Headings. Captions, sections and headings herein have been inserted
solely for convenience of reference and in no way limit the scope or substance of any provision of this Agreement.

 

		21.	Severability. If any of the provisions of this Agreement is held to be excessively broad
by any agency, tribunal or court of competent jurisdiction, it shall be reformed and construed by limiting and reducing it so as
to be enforceable to the maximum extent permitted by law. If any portion or provision of this Agreement shall to any extent be
declared illegal or unenforceable by any agency, tribunal or court of competent jurisdiction, even after the reformation and construction
as described in the preceding sentence, then the remainder of this Agreement, or the application of such portion or provision in
circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each
portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.

 

		22.	Injunctive Relief. Executive acknowledges and agrees that the Company’s remedies at
law for a breach or threatened breach of this Agreement would be inadequate and, in recognition of this fact, Executive agrees
that, in the event of such a breach or threatened breach, in addition to any remedies at law, the Company, without posting any
bond, shall be entitled to obtain equitable relief in the form of specific performance, temporary restraining orders, temporary
or permanent injunctions or any other equitable remedy which may then be available.

 

		23.	Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE
LAWS OF THE STATE OF GEORGIA APPLICABLE TO CONTRACTS EXECUTED AND PERFORMED IN SUCH STATE WITHOUT GIVING EFFECT TO CONFLICTS OF
LAWS PRINCIPLES. BECAUSE DISPUTES ARISING IN CONNECTION WITH COMMERCIAL MATTERS, INCLUDING EMPLOYMENT AGREEMENTS, ARE MOST QUICKLY
AND ECONOMICALLY RESOLVED BY AN EXPERIENCED AND EXPERT PERSON AND THE PARTIES WISH APPLICABLE STATE AND FEDERAL LAWS TO APPLY (RATHER
THAN ARBITRATION RULES), THE PARTIES DESIRE THAT THEIR DISPUTES (IF ANY) BE RESOLVED BY A JUDGE APPLYING SUCH APPLICABLE LAWS.
THEREFORE, TO ACHIEVE THE BEST COMBINATION OF THE BENEFITS OF THE JUDICIAL SYSTEM AND OF ARBITRATION, THE PARTIES HERETO WAIVE
ALL RIGHTS TO TRIAL BY JURY IN ANY ACTION, SUIT, OR PROCEEDING BROUGHT TO RESOLVE ANY DISPUTE, WHETHER ARISING IN CONTRACT, TORT,
OR OTHERWISE BETWEEN THE PARTIES ARISING OUT OF, CONNECTED WITH, RELATED TO, OR INCIDENTAL TO THE RELATIONSHIP ESTABLISHED BETWEEN
THEM IN CONNECTION WITH THIS EMPLOYMENT AGREEMENT OR MATTERS RELATED HERETO.

 

    -13- 

    	Inhibikase Therapeutics, Inc.
	Employment Agreement
	Milton H. Werner, Ph.D.

    

 

		24.	Opportunity to Obtain Counsel. In connection with the preparation of this Agreement, Executive
acknowledges and agrees that: (a) Executive has been advised that his interests may be opposed to the interests of Company and,
accordingly, Company counsel’s representation in the negotiation of this Agreement may not be in the best interests of Executive;
and (b) Executive has retained separate legal counsel. Executive warrants and agrees that he has read and fully understands the
terms and conditions of this Agreement. By signing this Agreement, Executive is affirming that he has freely and of Executive’s
own volition acknowledged and agreed to all terms and conditions contained in this Agreement.

 

		25.	Construction and Interpretation. Should any provision of this Agreement require judicial
interpretation, the parties hereto agree that the court interpreting or construing the same shall not apply a presumption that
the terms hereof shall be more strictly construed against one party by reason of the rule of construction that a document is to
be more strictly construed against the party that itself, or through its agent, prepared the same, and it is expressly agreed and
acknowledged that Company and Executive and each of his and its representatives, legal and otherwise, have participated in the
preparation hereof.

 

		26.	No Third Party Beneficiary. The terms and provisions of this Agreement are intended solely
for the benefit of each party hereto and Company’s successors or assigns, and it is not the intention of the parties to confer
third-party beneficiary rights upon any other person.

 

		27.	Waiver. No waiver of any provision hereof shall be effective unless made in writing and
signed by the waiving party. The failure of either party to require the performance of any term or obligation of this Agreement,
or the waiver by either party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation
or be deemed a waiver of any subsequent breach.

 

		28.	Counterparts. This Agreement may be executed in two or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument, and in pleading or proving
any provision of this Agreement it shall not be necessary to produce more than one such counterpart. No counterpart shall be effective
until each party has executed at least one counterpart. For the convenience of the parties, facsimile and pdf signatures shall
be accepted as originals.

 

[signature
page follows]

 

    -14- 

    	Inhibikase Therapeutics, Inc.
	Employment Agreement
	Milton H. Werner, Ph.D.

    

 

IN WITNESS WHEREOF,
the parties hereto have duly executed this Agreement as a binding contract as of the date first above written.

 

	COMPANY	 	EXECUTIVE
	 	 	 
	INHIBIKASE THERAPEUTICS, INC.	 	MILTON H. WERNER, PH.D.
	 	 	 
	 	 	By: /s/ Milton Werner
	By:	  /s/ Lisa Evrén	 	 
	 	Lisa Evrén, Director	 	 
	 	 	 	 
	 	 	 	 
	By:	  /s/ Anthony Zook	 	 
	 	Anthony Zook, Director	 	 
	 	 	 	 
	 	 	 	 
	By:	  /s/ Steven Gilman	 	 
	 	Steven Gilman, PhD, Director	 	 
	 	 	 	 
	 	 	 	 
	By:	  /s/ Peter Mueller	 	 
	 	Peter Mueller, PhD, Director	 	 

 

    -15-Exhibit 10.7

 

	Inhibikase Therapeutics, Inc.	Employment Agreement	Milton H. Werner, Ph.D.

 

EMPLOYMENT
AGREEMENT

 

THIS
EMPLOYMENT AGREEMENT (the “Agreement”), effective as of the closing of the initial public offering (the
 “Effective Date”) of Inhibikase Therapeutics, Inc., a Delaware corporation, with its principal place of business located
at 3350 Riverwood Parkway, Suite 1900, Atlanta, Georgia 30339 (the “Company”) is entered into by and between Milton
H. Werner, Ph.D., an individual currently residing at 874 Birds ML SE, Marietta, Georgia, 30067 (“Executive”) and the
Company. Except as otherwise defined herein, capitalized terms and phrases shall have the meaning ascribed thereto in Section 13
of this Agreement.

 

WHEREAS,
the Company and Executive desire to set forth the terms and conditions under which Executive shall be employed, and upon which
Executive shall be compensated by the Company.

 

WHEREAS,
the Company desires to continue to employ Executive as its President and Chief Executive Officer for the period and upon the terms
and conditions set forth in this Agreement.

 

WHEREAS,
Executive desires to serve in such capacities for such period and upon such terms.

 

WHEREAS,
the Company and Executive are entering into a separate registration rights agreement with respect to certain securities issued
by the Company and owned by Executive.

 

NOW
THEREFORE, in consideration of the foregoing recitals, the mutual promises and agreements hereinafter set forth, and
for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Executive
agree as follows:

 

		1.	Term. The Company agrees to employ Executive, and Executive accepts such employment with
the Company, upon the terms and subject to the conditions set forth in this Agreement. Executive’s employment shall commence
as of the Effective Date and shall continue until terminated in accordance with this Agreement (the “Term”).

 

		2.	Title; Duties; Board; Principal Place of Employment.

 

		(a)	Title; Duties. During the Term, Executive shall serve as the President and Chief Executive
Officer of the Company, reporting directly to the Company’s Board of Directors (the “Board”). Executive shall
perform such specific duties as are commensurate with such positions and such other duties as may be assigned to Executive from
time to time by the Board.

 

		(b)	Board. During the Term, Executive will be nominated to serve as a member of the Board for
each election of the Board; provided, however, that Executive’s continued service as a member of the Board will be
subject to any required stockholder approval. Upon any cessation of Executive’s employment, unless otherwise requested by
the Board, Executive agrees to resign from all director and officer positions with the Company and its affiliates.

 

     

     

    

 

		(c)	Principal Place of Employment. Currently, the Company has operations in both Atlanta, Georgia
and Boston, Massachusetts. During the Term, Executive will be expected to provide services in both locations. In the event the
Company consolidates its operations in a single location that is more than seventy-five miles from Executive’s principal
residence as of the Effective Date, the Company shall reimburse Executive for all expenses incurred by Executive within six (6)
months of the date of the office relocation for his reasonable travel to and from the new office location, temporary lodging near
such location, and relocation expenses, up to a maximum of $200,000 that is incurred in the calendar year in which the office relocation
occurs.

 

		3.	Outside Activities. Executive shall serve the Company faithfully and to the best of his
ability, shall use his business judgment, skill and best efforts to the advancement of the interests of the Company during the
Term. Executive shall not engage, directly or indirectly, in any other business, investment or activity that (a) interferes with
the performance of Executive’s duties under this Agreement, (b) is contrary to the interests of the Company or any of its
affiliates or (c) requires any portion of Executive’s business time; provided, however, that, to the extent that the following
does not impair Executive’s ability to perform Executive’s duties pursuant to this Agreement, Executive, with the Board’s
prior written approval (which approval may be withheld in the sole discretion of the Board), may serve on the board or committee
of any non-profit, educational, religious, charitable or other similar organization, may have speaking engagements, and may serve
as a member of the Board of Directors or equivalent of other organizations or companies (collectively, “Outside Activities”),
provided, however, that if, after it provides prior written approval for an Outside Activity, the Board determines in good
faith that such Outside Activity is inconsistent with applicable law or Company policy, or conflicts with Executive’s obligations
under this Agreement, Executive will cease any such Outside Activity upon written notice from the Board.

 

		4.	Cash Compensation.

 

		(a)	Base Salary. During the Term of this Agreement, Executive shall receive a base salary at
a gross rate of $37,916.67 per month ($455,000 per annum) (the “Base Salary”), payable in substantially equal installments
in accordance with the Company’s normal payroll practices for payment of its employees, as in effect from time to time. Executive’s
Base Salary shall be subject to upward adjustment from time to time, as determined by the Board (or a committee thereof) in its
sole discretion, but shall not be adjusted downward.

 

		(b)	Bonuses - Other Compensation. Executive shall be eligible to receive a target annual performance
cash bonus of 35% of Executive’s then-Base Salary (“Annual Target Bonus”). Executive’s Annual Target Bonus
is not guaranteed and will be based on the Company’s performance and/or Executive’s individual performance as determined
by the Compensation Committee of the Board (the “Committee”) in its discretion. The actual payout for this award will
be calculated based solely on achievement against performance measures approved by the Committee. Each year, specific targets will
be approved by the Committee in the year’s first quarter and communicated to Executive following such approval. Performance
against these goals will be assessed after year end, with payout made no later than March 15 of the year following the year in
respect of which the bonus was earned, subject to Executive’s continued employment through the payment date.

 

    -2-

     

    

 

In addition, during the Term of
this Agreement, the Board, in its sole discretion, may award additional compensation to Executive other than as specifically provided
by this Agreement.

 

		5.	Equity Compensation.

 

		(a)	Initial Stock Option Grants As soon as practicable following consummation of the Company’s
initial public offering of stock, Executive will be granted a stock option to purchase One Hundred Thousand (100,000) shares of
Company common stock, pursuant to the Company’s nonqualified stock option agreement under the Company’s 2011 Equity
Incentive Plan or a successor thereto (the “Plan”). One-third of the grant shall vest and become exercisable on the
first anniversary of the Effective Date, and the remaining portion will vest and become exercisable in 24 equal monthly installments
commencing on the first day of the month following the first anniversary of the Effective Date, subject to Executive’s continued
employment through each such vesting date.

 

		(b)	Equity Grants. In its sole discretion, the Board may grant to Executive from time to time
stock options to purchase shares of Company common stock or such other equity awards as it may determine.

 

		6.	Executive Benefits.

 

		(a)	Generally. During the Term of this Agreement, Executive shall be eligible to participate
in all benefit and fringe benefit plans made available to other executive officers of the Company. Any such participation shall
be subject to the terms and conditions of the applicable plan documents, applicable law, generally applicable Company policies,
and the discretion of the Company, all as provided for in or contemplated by such plans. Subject to the terms of such plans and
applicable law, the Company may alter, modify, add to or delete its employee benefit plans at any time, in its sole discretion,
without recourse by Executive.

 

		(b)	Vacation. Executive shall be entitled to four (4) weeks per year paid vacation time as provided
in the Company’s vacation policies and procedures as in effect from time to time. Executive may take accrued vacation at
such time or times as are mutually agreed upon by Executive and the Company. All matters relating to vacation time, including but
not limited to accrual, carryover and forfeiture of vacation time, shall be governed by, and Executive agrees to be bound by, the
Company’s policies and procedures regarding vacation time as in effect from time to time.

 

    -3-

     

    

 

		(c)	Paid Sick Leave. Executive will be eligible for paid sick leave (“Earned Sick Time”)
under the Massachusetts Earned Sick Time Law. All 40 hours of Earned Sick Time are fully accrued on January 1 of each calendar
year and unused time cannot be carried over to future years. For 2018, Executive will receive 20 hours of accrued Earned Sick Time
on the first day of the Term.

 

		7.	Expenses. The Company will reimburse Executive for reasonable travel, entertainment and
other expenses incurred by Executive in the furtherance of the performance of Executive’s duties hereunder, in accordance
with the Company’s expense reimbursement policy as in effect from time to time. The Company and/or the Board may periodically
audit or review such expenses to ensure they are for legitimate business expenses.

 

		8.	Deduction and Withholding. Notwithstanding any other provision of this Agreement, any payments
or benefits hereunder shall be subject to the withholding of such amounts, if any, relating to tax and other payroll deductions,
as the Company reasonably determines it should withhold pursuant to any applicable law or regulation.

 

		9.	Termination of Agreement.

 

		(a)	Termination Date. Executive’s employment and this Agreement (except as otherwise provided
hereunder) shall terminate upon the first to occur of any of the following, at the time set forth therefore (the “Termination
Date”):

 

		(i)	Mutual Termination. At any time by the mutual written agreement of Company and Executive;

 

		(ii)	Death or Disability. Immediately upon the death of Executive or, subject to applicable law, a determination
by Company that Executive has a Disability;

 

		(iii)	Voluntary Termination By Executive. 90 days following Executive’s written notice to Company
of termination of employment; provided, however, that Company may waive all or a portion of such notice period and accelerate
the effective date of such termination (termination pursuant to this Subsection being referred to herein as “Voluntary”
termination);

 

		(iv)	Termination For Cause By Company. Immediately following notice of termination for “Cause”
given by Company (as defined below) and failure by Executive to Cure (as defined below), if applicable, with such notice specifying
such Cause (termination pursuant to this Subsection being referred to herein as termination for “Cause”);

 

		(v)	Termination Without Cause By Company. The Company may terminate without Cause Executive’s
employment under this Agreement at any time (termination pursuant to this Subsection being referred to herein as termination “Without
Cause”); or

 

    -4-

     

    

 

		(vi)	Termination For Good Reason by Executive. Subject to the notice and remedy provisions described
in Section 14(d) below, at the election of Executive for Good Reason so long as the Separation From Service (as such phrase is
defined in Code Section 409A; Treasury Regulations Section 1.409A-1(h)) on account of any such condition occurs not later than
sixty (60) days following the expiration of the thirty-day (30-day) remedy period described in Section 14(d) below.

 

		(b)	No limitation on Remedies. Termination pursuant to this Section 9 shall be in addition to and without
prejudice to any other right or remedy to which Company may be entitled at law, in equity, or under this Agreement.

 

		10.	Basics Rights at Termination. In the event Executive’s employment with the Company
is terminated for any reason, Executive will be entitled to any (a) unpaid Base Salary accrued up to the effective date of termination;
(b) benefits or compensation as provided under the terms of any employee benefit and compensation agreements or plans applicable
to Executive; (c) unreimbursed business expenses required to be reimbursed to Executive in accordance with and subject to Company’s
policies applicable thereto; and (d) rights of indemnification to which Executive may be entitled as of the Termination Date under
the Company’s Articles of Incorporation, Bylaws, this Agreement, or separate indemnification agreement, as applicable. In
addition, Executive will be entitled to the amounts and benefits specified in Section 11 of this Agreement, to the extent applicable.

 

		11.	Termination Benefits.

 

		(a)	Termination Without Cause or Resignation for Good Reason other than In Connection with a Change
of Control. If Executive’s employment is terminated by the Company without Cause or if Executive resigns for Good Reason,
and such termination is not In Connection with a Change of Control, then, subject to Section 11(f), Executive will receive: (i)
payment of an aggregate amount equal to Executive’s monthly Base Salary as is in effect on the Termination Date multiplied
by 12 (less applicable tax withholdings), such amounts to be paid out monthly in substantially equal installments over the six
month period following such termination in accordance with the Company’s normal payroll policies; (ii) payment of the annual
bonus (pursuant to Section 4(b)) accrued for the year prior to such termination (to the extent not already paid); (iii) payment
of Executive’s annual bonus for the year of such termination, to the extent Executive would have received such bonus had
Executive remained employed through the applicable payment date of such bonus, appropriately pro-rated based on the number of days
that Executive was employed by the Company during the year of the termination, paid when the Company’s other senior executive
receive payment of their annual bonuses; (iv) full vesting with respect to Executive’s then outstanding, unvested equity
awards that were awarded under the Company’s 2011 Equity Incentive Plan; (v) extension of the exercise period for all of
Executive’s then outstanding vested stock options (including those that vested pursuant to clause (iii) herein) to the first
to occur of: the 6 month anniversary of the date of termination, the expiration date of the stock options, or such earlier time
as provided under the applicable plan or grant agreement with respect to a Change of Control; and (vi) reimbursement for premiums
paid for continued health benefits for Executive (and any eligible dependents) under the Company’s health plans until the
earlier of (x) twelve (12) months, payable when such premiums are due (provided Executive validly elects to continue coverage under
the Consolidated Omnibus Budget Reconciliation Act (“COBRA”) or similar state law or (y) the date upon which Executive
and Executive’s eligible dependents become covered under similar plans.

 

    -5-

     

    

 

		(b)	Termination Without Cause or Resignation for Good Reason In Connection with a Change of Control.
If Executive’s employment is terminated by the Company without Cause or by Executive for Good Reason, and the termination
is In Connection with a Change of Control, then, subject to Section 11(f), Executive will receive: (i) payment of an aggregate
amount equal to Executive’s monthly Base Salary as is in effect on the Termination Date multiplied by 18 (less applicable
tax withholdings), such amounts to be paid out in substantially equal installments over the twelve month period following such
termination in accordance with the Company’s normal payroll policies; (ii) payment of the annual bonus (pursuant to Section
4(b)) accrued for the year prior to such termination (to the extent not already paid); (iii) Executive’s then-current Annual
Target Bonus; (iv) a pro-rata portion of Executive’s Annual Target Bonus for the year of such termination paid in lump sum;
(v) full vesting with respect to Executive’s then outstanding, unvested equity awards that were granted under any of the
Company’s equity incentive plans; (vi) extension of the exercise period for all of Executive’s outstanding stock options
to the first to occur of: the 6 month anniversary of the date of termination, the expiration date of the stock options, or such
earlier time as provided under the applicable plan or grant agreement with respect to a Change of Control; and (vii) reimbursement
for premiums paid for continued health benefits for Executive (and any eligible dependents) under the Company’s health plans
until the earlier of (x) eighteen (18) months, payable when such premiums are due (provided Executive validly elects to continue
coverage under COBRA or similar state law), or (y) the date upon which Executive and Executive’s eligible dependents become
covered under similar plans.

 

		(c)	Voluntary Termination Without Good Reason or Termination for Cause. If Executive’s
employment is terminated voluntarily by him without Good Reason or is terminated for Cause by the Company, then, except as otherwise
provided in the first sentence of Section 10 above or Section 11(e), (i) all further vesting of Executive’s outstanding equity
awards will terminate immediately; and (ii) all payments of compensation by the Company to Executive hereunder will terminate immediately.

 

		(d)	Termination Due to Death or Disability. If Executive’s employment is terminated due
to death or Disability, and (x) such termination is not In Connection With a Change of Control, all outstanding, unvested equity
awards that were awarded under the 2011 Plan will then vest, or (y) such termination is In Connection With a Change of Control,
all outstanding, unvested equity awards granted under any of the Company’s equity incentive plans will then vest. All outstanding
vested stock options (including those that vested under (x) or (y) herein, will remain exercisable until the first to occur of:
the 6 month anniversary of the date of termination, the expiration date of the stock options, or such earlier time as provided
under the applicable plan or grant agreement with respect to a Change of Control. Except as otherwise provided in this Section
11(d), the first sentence of Section 10 above, or Section 11(e), all payments of compensation by the Company to Executive hereunder
will terminate immediately upon Executive’s termination.

 

    -6-

     

    

 

		(e)	Other Terminations. If Executive’s employment is terminated due to any reason other
than a termination by the Company without Cause, voluntary termination by Executive with Good Reason, or a termination due to Executive’s
death, Executive will receive an aggregate amount equal to fifty percent (50%) of Executive’s highest annualized Base Salary
paid in the two years preceding the termination. Such amount shall be paid out monthly in substantially equal installments in accordance
with the Company’s normal payroll practices, (i) over the six (6) month period following such termination, if the termination
was not In Connection With a Change in Control, or (ii) over the twelve (12) month period following such termination, if the termination
was In Connection With a Change in Control.

 

		(f)	Separation Agreement and Release of Claims. The receipt of any severance or other benefits
pursuant to Sections 11(a) or 11(b) will be subject to and conditioned on Executive first signing and not otherwise revoking a
separation agreement and release of claims in substantially the form appended hereto as Exhibit A (the “Release Agreement”),
which Release Agreement shall contain Executive’s affirmation of his obligation not to compete with the Company as described
in Section 15 herein. For this purpose, the Release Agreement must be signed by Executive and returned to the Company no later
than thirty (30) days following the Termination Date in accordance with the terms of the Release Agreement. Notwithstanding any
other provision of this Agreement to the contrary, no severance or other benefits will be paid or provided unless the Release Agreement
becomes effective, and any severance amounts or benefits otherwise payable between the Termination Date and the forty-fifth (45th)
day following the Termination Date will be paid on such forty-fifth (45th) day.

 

		(g)	Consideration for Non-Competition After Termination. Executive acknowledges that the cash
payments described in Sections 11(a), 11(b), and 11(e), the initial stock option grant described in Section 5(a), as well as the
other consideration set forth in this Agreement constitute (A) fair and reasonable consideration for purposes of Section 24L(b)(ii)
of Chapter 149 of the Massachusetts General Laws, and (B) mutually agreed upon consideration for purposes of Section 24L(b)(vii)
of Chapter 149 of the Massachusetts General Laws.

 

    -7-

     

    

 

		(h)	No Duty to Mitigate. Executive will not be required to mitigate the amount of any payment
contemplated by this Agreement, nor will any earnings that Executive may receive from any other source reduce any such payment.

 

		12.	Section 280G; Parachute Payments.

 

If any payment or distribution
by the Company to or for the benefit of Executive, whether paid or payable or distributed or distributable pursuant to the terms
of this Agreement or otherwise pursuant to or by reason of any other agreement, policy, plan, program or arrangement or the lapse
or termination of any restriction on or the vesting or exercisability of any payment or benefit (each a “Payment”),
would be subject to the excise tax imposed by Code Section 4999 (or any successor provision thereto) or to any similar tax imposed
by state or local law (such tax or taxes are hereafter collectively referred to as the “Excise Tax”), then the aggregate
amount of Payments payable to Executive shall be reduced to the aggregate amount of Payments that may be made to Executive without
incurring an excise tax (the “Safe-Harbor Amount”) in accordance with the immediately following sentence; provided
that such reduction shall only be imposed if the aggregate after-tax value of the Payments retained by Executive (after giving
effect to such reduction) is equal to or greater than the aggregate after-tax value (after giving effect to the Excise Tax) of
the Payments to Executive without any such reduction. Any such reduction shall be made in the following order: (i) first, any future
cash payments (if any) shall be reduced (if necessary, to zero); (ii) second, any current cash payments shall be reduced (if necessary,
to zero); (iii) third, all non-cash payments (other than equity or equity derivative related payments) shall be reduced (if necessary,
to zero); and (iv) fourth, all equity or equity derivative payments shall be reduced.

 

		13.	Definitions.

 

		(a)	Cause. (A) Executive’s conviction of or plea of nolo contendere to a felony; (B) Executive’s
commission of fraud, misappropriation or embezzlement against any person; (C) the theft or misappropriation by Executive of any
property or money of the Company or an affiliate; (D) Executive’s breach of the terms of this Agreement; or (E) the willful
or gross neglect of Executive’s duties, the willful or gross misconduct in performance of Executive’s duties or the
willful violation by Executive of any material Company policy. Notwithstanding the foregoing, Cause shall not exist with respect
to subsection (D) or (E), until and unless Executive fails to cure such breach, neglect or misconduct (if such breach, neglect
or misconduct is capable of cure) within 10 days after written notice from the Board.

 

		(b)	Code shall mean the Internal Revenue Code of 1986, as amended from time to time.

 

		(c)	Change of Control. For purposes of this Agreement, “Change of Control” will
mean the occurrence of any of the following events:

 

		(i)	The consummation by the Company of a merger or consolidation of the Company with any other corporation,
other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto
continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity)
more than 50% of the total voting power represented by the voting securities of the Company or such surviving entity outstanding
immediately after such merger or consolidation;

 

    -8-

     

    

 

		(ii)	The approval by the stockholders of the Company, or if stockholder approval is not required, approval
by the Board, of either (1) a plan of complete liquidation of the Company or (2) an agreement for the sale or disposition by the
Company of all or substantially all of the Company’s assets; or

 

		(iii)	Any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange
Act of 1934, as amended) becoming the “beneficial owner” (as defined in Rule 13d-3 under said Act), directly or indirectly,
of securities of the Company representing 50% or more of the total voting power represented by the Company’s then outstanding
voting securities.

 

Notwithstanding the foregoing,
a Change of Control will not be deemed to have occurred unless such event would also be a Change in Control under Code Section
409A or would otherwise be a permitted distribution event under Code Section 409A.

 

		(d)	Disability. For purposes of this Agreement, “Disability” will mean Executive’s
inability to substantially perform his duties under this Agreement as a result of incapacity by reason of any medically determinable
physical or mental impairment that can be expected to result in death or to last for a period of twelve (12) months.

 

		(e)	Good Reason. For purposes of this Agreement, “Good Reason” means the occurrence
of any of the following conditions, without Executive’s express written consent; provided, however, that Executive’s
employment is terminated no later than one hundred eighty (180) days following the initial existence of one or more of the following
conditions; provided further, that Executive must provide the Company notice of Good Reason within ninety (90) days of the initial
existence of one of the following conditions, upon which notice the Company shall then have thirty (30) days in which to remedy
the condition, under which circumstances the Company shall not be required to pay any amounts specified in Section 11 of this Agreement:

 

		(i)	A material diminution in Executive’s authority, duties or responsibilities in effect immediately
prior to such diminution;

 

		(ii)	A material diminution in Executive’s Base Salary that persists for longer than 12 months;
or

 

		(iii)	Any other action or inaction that constitutes a material breach by the Company of this Agreement.

 

    -9-

     

    

 

		(f)	In Connection with a Change of Control. For purposes of this Agreement, a termination by
Company of Executive’s employment with the Company is “In Connection with a Change of Control” if Executive’s
employment is terminated by Company without Cause or by Executive for Good Reason within twelve (12) months following a Change
of Control.

 

		14.	Return of Company Property and Records. Upon any termination of employment for any reason
or no reason, or upon the Company’s request at any time, Executive shall immediately return to the Company all property of
the Company in Executive’s possession (including computers, smart phones and other portable electronic devices) and all documents
and other materials in any medium including but not limited to electronic, which relate in any way to the Company, including notebooks,
correspondence, memos, drawings or diagrams, computer files and databases, graphics and formulas, whether prepared by Executive
or by others and whether required by Executive’s work or for his or her personal use, whether copies or originals, unless
Executive first obtains the Company’s written consent to keep such records.

 

		15.	Non-Competition. In consideration of the rights and benefits hereunder, including but not
limited to the payments and benefits referenced in Section 11(g), Executive agrees that so long as he or she is an employee of
the Company and for a period of twelve (12) months after the date of termination of Executive’s employment for any reason
(the “Restricted Period”), Executive shall not, without the prior written consent of the Company, own any interest
in, control, participate in, work for, become employed by, or provide services to (whether as an employee, consultant, independent
contractor or otherwise) any individual or entity that competes with the Company in the area of neurodegeneration therapeutics
development in the United States. This Section 15 shall survive the termination of this Agreement.

 

		16.	Non-Solicitation. In consideration of the rights and benefits hereunder, Executive agrees
that during the Restricted Period, he or she shall not, without the prior written consent of the Company: (i) solicit or encourage
any employee of the Company or its affiliates to leave the employment of the Company or such affiliate; or (ii) solicit or encourage
any client of the Company or any of its affiliates (including any investors in funds managed by the Company or its affiliates)
to cease to do business with the Company or its affiliates. The only exceptions to the restrictions in this paragraph are: (i)
clients (if any) with which Executive had a significant and provable business relationship prior to his/her employment with the
Company, and (ii) where Executive has the express, prior written consent of the Board to be released in whole or part from this
section of the Agreement. This Section 16 shall survive the termination of this Agreement.

 

    -10-

     

    

 

		17.	Confidentiality. Executive agrees that during Executive’s employment with the Company,
will have access to confidential information and/or proprietary information about the Company and/or its clients, including, but
not limited to, investment strategies, programs or ideas, trade secrets, methods, models, passwords, access to computer files,
financial information and records, forecasts, computer software programs, agreements and/or contracts between the Company and its
respective clients, client contracts, prospective contracts, creative policies and ideas, public relations and public affairs campaigns,
media materials, budgets, practices, concepts, strategies, methods of operation, technical and scientific information, discoveries,
developments, formulas, specifications, know-how, design inventions, marketing and business strategies and financial or business
projects, and information about or received from clients and other companies with which the Company does business. The foregoing
shall be collectively referred to as “Confidential Information.” Any information that is not readily available to the
public shall be considered to be Confidential Information, even if it is not specifically marked as such, unless the Company advises
Executive otherwise in writing. Such Confidential Information is not readily available to the public and accordingly, Executive
agrees that he or she will not at any time, whether during his or her employment with the Company or thereafter, disclose to anyone,
(other than in furtherance of the business of the Company) any Confidential Information, or utilize such Confidential Information
for his or her own benefit, or for the benefit of third parties. Executive also agrees to preserve and protect the confidentiality
of any third party information similar to the Confidential Information to the same extent, and on the same basis, as the Company’s
Confidential Information. To the extent that any Confidential Information shall become the subject of any search warrant, court
order, lawful subpoena, governmental investigation disclosure request or mandate, or the like (a “Disclosure Request”),
Executive will notify the Company immediately, provide the Company adequate opportunity to oppose such Disclosure Request and reasonably
assist the Company, at no cost to Executive, in opposing such Disclosure Request or seeking a protective order or such other limitation
on disclosure as may be reasonably requested by the Company. If, after providing the notice and assistance required by the immediately
preceding sentence, Executive is still required by lawful order to disclose any Confidential Information, Executive shall only
disclose such information as is specifically required by such lawful order. The confidentiality protections available in this Agreement
are in addition to, and not exclusive of, any and all other rights, including those provided under copyright, officer or director
fiduciary duties and trade secret and confidential information laws. This confidentiality covenant has no temporal, geographical
or territorial restriction. This Section 17 shall survive the termination of this Agreement.

 

Notwithstanding
anything herein to the contrary, nothing in this Agreement shall (x) prohibit Executive from making reports of possible violations
of federal law or regulation to any governmental agency or entity in accordance with the provisions of and rules promulgated under
Section 21F of the Securities Exchange Act of 1934, as amended, or Section 806 of the Sarbanes-Oxley Act of 2002, or of any other
whistleblower protection provisions of federal law or regulation, or (y) require notification or prior approval by the Company
of any such report; provided that, Executive is not authorized to disclose communications with counsel that were made for the purpose
of receiving legal advice or that contain legal advice or that are protected by the attorney work product or similar privilege.

 

DEFEND TRADE SECRETS ACT NOTICE
AND RELATED PROVISIONS: The Defend Trade Secrets Act of 2016 provides as follows: (1) An individual shall not be held criminally
or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made in confidence to
a federal, state or local government official or to an attorney and such disclosure is made (a) solely for the purpose of reporting
or investigating a suspected violation of law or (b) in a complaint or other document filed in a lawsuit or other proceeding if
such filing is made under seal. (2) An individual may disclose a trade secret to that individual’s attorney for the purpose
of filing a lawsuit for retaliation by an employer for reporting a suspected violation of law and use the trade secret information
in the court proceeding provided the individual files any document containing the trade secret under seal and the individual does
not disclose the trade secret except pursuant to court order. The Defend Trade Secrets Act also provides that a court enforcing
that law may, if a trade secret is found to have been willfully and maliciously misappropriated, award (a) “exemplary damages”
in an amount of up to two times the amount of damages awarded for actual loss caused by the misappropriation of a trade secret
and damages for unjust enrichment caused by the misappropriation of the trade secret, or a reasonable royalty for the misappropriation,
and (b) reasonable attorneys’ fees against the misappropriating party.

 

    -11-

     

    

 

		18.	Intellectual Property Assignment. For the purposes of this Agreement, the “business
of the Company” is defined as the research and development, manufacturing, production, sales, and distributions of small-molecule
kinase inhibitor therapeutics. In the course of Executive’s employment, Executive may develop, conceive, generate, or contribute
to, alone and/or jointly with others, tangible and intangible property including without limitation, inventions, improvements,
business systems, works of authorship, algorithms, software, hardware, knowhow, designs, techniques, methods, documentation and
other material, regardless of the form or media in or on which it is stored, some or all of which property may be protected by
patents, copyrights, trade secrets, trade-marks, industrial designs or mask works, that relates to the business of the Company
or to the Company’s actual or demonstrably anticipated research and development, or relates to or incorporates any Confidential
Information, and whether or not made on the Company’s time or premises or using the Company’s resources, equipment,
supplies or facilities, (which tangible and intangible property is collectively referred to in this Agreement as “Proprietary
Property”).

 

All right,
title and interest in and to Confidential Information and Proprietary Property (including, without limitation, the Proprietary
Property described below), belongs to the Company, and Executive has no rights in any such Confidential Information and Proprietary
Property. For greater certainty, all right, title and interest (including without limitation any intellectual property rights)
in and to all Confidential Information and Proprietary Property that Executive may acquire or hold in the course of his or her
employment is hereby assigned to the Company. Executive acknowledges that a Company customer or other third party (referred to
in this Agreement as “Customer”) may, under the terms of its agreement with the Company, own the applicable right,
title and interest (including without limitation any intellectual property rights) in certain Proprietary Property (referred to
in this Agreement as “Customer Proprietary Property”) and Executive agrees to abide by any and all terms of said Customer
agreements as they relate to Customer Proprietary Property and Customer confidential information.

 

Executive
agrees that all of the work product that Executive helps to develop while employed with the Company is the exclusive property and
Confidential Information of the Company. Any such work product will be considered to be a work made for hire. Executive agrees
to make full disclosure to the Company of and to properly document any development of Proprietary Property that Executive is involved
in, and to provide written documentation describing such development to the Company, promptly after its creation. At the request
and expense of the Company, both during and after employment, Executive will do all acts necessary and sign all documentation requested
by the Company in order to assign all right, title and interest in and to the Proprietary Property to the Company (or to the applicable
Customer, in relation to Costumer Proprietary Property) and to enable the Company (or the applicable Customer in relation to Customer
Proprietary Property) to register (and to assist the Company to protect and defend its rights in and under any) patents, copyrights,
trademarks, trade secrets, mask works, industrial designs and such other protections as the Company (or such Customer) deems advisable
anywhere in the world. Executive hereby constitutes and appoints the Company and each and every director of the Company as Executive’s
true and lawful attorney with full power of substitution in Executive’s name of and on Executive’s behalf with no restriction
or limitation in that regard, to execute and deliver all such documentation as may be necessary to permit any intellectual property
application to be completed as provided in this Agreement; the foregoing power of attorney shall be irrevocable (to the fullest
extent permitted by law) and is a power coupled with an interest and shall bind Executive and Executive’s heirs, executors
and legal personal representatives.

 

    -12-

     

    

 

All notes,
data, tapes, reference items, sketches, drawings, memoranda, records, documentation and other material regardless of the form or
media in or on which it is stored, that is in or comes into Executive’s possession or control, and that is in any way obtained,
developed, conceived, generated or contributed to by Executive, alone and/or jointly with others, during or as a result of Executive’s
employment, is and remains Proprietary Property within the meaning of this Agreement.

 

The Company
and Executive agree and understand that the Company claims no right and agrees to release to Executive all rights in any tangible
or intangible property, provided that (i) it was developed by Executive entirely on Executive’s own time, without using the
Company’s or any Customer’s resources, equipment, supplies, facilities, or funds, (ii) it does not relate to the business
of the Company or Customer or to the Company’s or Customer’s actual or demonstrably anticipated research and development,
(iii) it does not relate to or incorporate any Confidential Information or result from any work performed by Executive for the
Company or the Customer; and (iv) it was disclosed by Executive to the Company promptly after its creation.

 

Without limiting
the generality of the foregoing, such property includes the excluded property listed on the attached Exhibit B. If disclosure would
cause Executive to violate any prior confidentiality agreement, Executive understands that Executive is not to list details of
such items in Exhibit B but instead to include a general/generic listing and to inform the Company that details have not been listed
for that reason. If there is no attached Exhibit B, there is no such excluded property.

 

		19.	Cooperation. Following the date of termination or expiration of this Agreement for any reason,
upon the receipt of reasonable notice from the Company (including outside counsel to the Company) or their affiliates, Executive
hereby agrees that he or she will respond and provide information with regard to matters in which he or she has knowledge as a
result of his or her employment and association with the Company. Executive also agrees that he or she will provide reasonable
assistance to the Company and its affiliates and their respective representatives in the defense of any claims that may be made
against the Company or any of its affiliates, and will assist the Company and its affiliates in the prosecution of any claims that
may be made by the Company or any of its affiliates to the extent that such claims may relate to the Term. Executive hereby agrees
to promptly inform the Company (to the extent Executive is legally permitted to do so) if Executive is asked to assist in any investigation
of the Company or any of its affiliates or their actions, regardless of whether a lawsuit or other proceeding has then been filed
with respect to such investigation. This Section 19 shall survive the termination of this Agreement.

 

    -13-

     

    

 

		20.	Indemnification. Subject to applicable law, Executive will be provided indemnification to
the maximum extent permitted by the Company’s Articles of Incorporation, Bylaws, this Agreement, or separate indemnification
agreement, as applicable, including, if applicable, any directors and officers insurance policies, with such indemnification to
be on terms determined by the Board or any of its committees, but on terms no less favorable than provided to any other Company
executive officer or director and subject to the terms of any separate written indemnification agreement.

 

		21.	Section 409A. The following rules shall apply, to the extent necessary, with respect to
distribution of the payments and benefits, if any, to be provided to Executive under this Agreement. Subject to the provisions
in this Section, the severance payments pursuant to this Agreement shall begin only upon the date of Executive’s “separation
from service” (determined as set forth below) which occurs on or after the date of Executive’s termination of employment.

 

		(a)	This Agreement is intended to comply with or be exempt from Code Section 409A and the parties hereto
agree to interpret, apply and administer this Agreement in the least restrictive manner necessary to comply therewith or be exempt
therefrom and without resulting in any increase in the amounts owed hereunder by the Company.

 

		(b)	It is intended that each installment of the severance payments and benefits provided under this
Agreement shall be treated as a separate “payment” for purposes of Section 409A of the Code and the guidance issued
thereunder (“Section 409A”). Neither Executive nor the Company shall have the right to accelerate or defer the
delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A.

 

		(c)	If, as of the date of Executive’s “separation from service” from the Company,
Executive is a “specified employee” (within the meaning of Section 409A), then: each installment of the severance payments
and benefits due under this Agreement that, in accordance with the dates and terms set forth herein, will in all circumstances,
regardless of when the separation from service occurs, be paid within the short-term deferral period (as defined in Section 409A)
shall be treated as a short-term deferral within the meaning of Treasury Regulation Section 1.409A-1(b)(4) to the maximum extent
permissible under Section 409A; and each installment of the severance payments and benefits due under this Agreement that is not
described in the preceding sentence and that would, absent this subsection, be paid within the six-month period following Executive’s
 “separation from service” from the Company shall not be paid until the date that is six months and one day after such
separation from service (or, if earlier, Executive’s death), with any such installments that are required to be delayed being
accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following Executive’s
separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein;
provided, however, that the preceding provisions of this sentence shall not apply to any installment of severance payments
and benefits if and to the maximum extent that such installment is deemed to be paid under a separation pay plan that does not
provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-1(b)(9)(iii) (relating to separation
pay upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation Section
1.409A-1(b)(9)(iii) must be paid no later than the last day of the second taxable year following the taxable year in which the
separation from service occurs.

 

    -14-

     

    

 

		(d)	The determination of whether and when Executive’s separation from service from the Company
has occurred shall be made in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section
1.409A-1(h). Solely for purposes of this Section, “Company” shall include all persons with whom the Company
would be considered a single employer as determined under Treasury Regulation Section 1.409A- 1(h)(3).

 

		(e)	All reimbursements and in-kind benefits provided under this Agreement shall be made or provided
in accordance with the requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section
409A, including, where applicable, the requirements that (i) any reimbursement is for expenses incurred during Executive’s
lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement
during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement
of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred
and (iv) the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit.

 

		(f)	Notwithstanding anything herein to the contrary, the Company shall have no liability to Executive
or to any other person if the payments and benefits provided in this Agreement that are intended to be exempt from or compliant
with Section 409A are not so exempt or compliant.

 

		22.	Notices. Any notice hereunder by either party to the other shall be given in writing by
personal delivery or by registered mail, return receipt requested, addressed, if to the Company, to the attention of the Company’s
Chairman of the Board of Directors at the Company’s principal offices or to such other address as the Company may designate
in writing to Executive, and if to Executive, to his most recent home address on file with the Company. Notice shall be deemed
given, if by personal delivery, on the date of such delivery or, if by registered mail, on the date shown on the applicable return
receipt.

 

    -15-

     

    

 

		23.	Entire Agreement; Modification. This Agreement constitutes the entire understanding and
agreement between the parties hereto with regard to the subject matter hereof, and supersedes all prior understandings and agreements,
whether written or oral. This Agreement may not be amended, supplemented, revised or otherwise modified except by a writing signed
by the parties hereto.

 

		24.	Assignment. This Agreement may not be assigned, in whole or in part, by any party without
the prior written consent of the other party, except that the Company may, without the consent of Executive, assign its rights
and obligations under this Agreement to any corporation, firm or other business entity with or into which the Company may merge
or consolidate, or to which the Company may sell or transfer all or substantially all of its assets. After any such assignment
by the Company, the Company shall be discharged from all further liability hereunder and such assignee shall have all the rights
and obligations of the Company under this Agreement.

 

		25.	Captions, Sections and Headings. Captions, sections and headings herein have been inserted
solely for convenience of reference and in no way limit the scope or substance of any provision of this Agreement.

 

		26.	Severability. If any of the provisions of this Agreement is held to be excessively broad
by any agency, tribunal or court of competent jurisdiction, it shall be reformed and construed by limiting and reducing it so as
to be enforceable to the maximum extent permitted by law. If any portion or provision of this Agreement shall to any extent be
declared illegal or unenforceable by any agency, tribunal or court of competent jurisdiction, even after the reformation and construction
as described in the preceding sentence, then the remainder of this Agreement, or the application of such portion or provision in
circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each
portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.

 

		27.	Injunctive Relief. Executive acknowledges and agrees that the Company’s remedies at
law for a breach or threatened breach of this Agreement would be inadequate and, in recognition of this fact, Executive agrees
that, in the event of such a breach or threatened breach, in addition to any remedies at law, the Company, without posting any
bond, shall be entitled to obtain equitable relief in the form of specific performance, temporary restraining orders, temporary
or permanent injunctions or any other equitable remedy which may then be available.

 

		28.	Governing Law. This Agreement shall be governed by and construed in accordance with the
laws of the Commonwealth of Massachusetts applicable to contracts executed and performed in such state without giving effect to
conflicts of laws principles.

 

		29.	Opportunity to Obtain Counsel; Acknowledgments. In connection with the preparation of this
Agreement, Executive acknowledges and agrees that: (a) Executive has been advised that his interests may be opposed to the interests
of Company and, accordingly, Company counsel’s representation in the negotiation of this Agreement may not be in the best
interests of Executive; and (b) Executive has been advised to and has so retained separate legal counsel. Executive warrants and
agrees that he has read and fully understands the terms and conditions of this Agreement. By signing this Agreement, Executive
is affirming that he has freely and of Executive’s own volition acknowledged and agreed to all terms and conditions contained
in this Agreement. Executive acknowledges that he had at least ten (10) business days to consider the terms of this Agreement prior
to it becoming effective in accordance with its terms.

 

    -16-

     

    

 

		30.	Construction and Interpretation. Should any provision of this Agreement require judicial
interpretation, the parties hereto agree that the court interpreting or construing the same shall not apply a presumption that
the terms hereof shall be more strictly construed against one party by reason of the rule of construction that a document is to
be more strictly construed against the party that itself, or through its agent, prepared the same, and it is expressly agreed and
acknowledged that Company and Executive and each of his and its representatives, legal and otherwise, have participated in the
preparation hereof.

 

		31.	No Third Party Beneficiary. The terms and provisions of this Agreement are intended solely
for the benefit of each party hereto and Company’s successors or assigns, and it is not the intention of the parties to confer
third-party beneficiary rights upon any other person.

 

		32.	Waiver. No waiver of any provision hereof shall be effective unless made in writing and
signed by the waiving party. The failure of either party to require the performance of any term or obligation of this Agreement,
or the waiver by either party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation
or be deemed a waiver of any subsequent breach.

 

		33.	Counterparts. This Agreement may be executed in two or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument, and in pleading or proving
any provision of this Agreement it shall not be necessary to produce more than one such counterpart. No counterpart shall be effective
until each party has executed at least one counterpart. For the convenience of the parties, facsimile and pdf signatures shall
be accepted as originals.

 

[signature page follows]

 

    -17-

     

    

 

IN
WITNESS WHEREOF, the parties hereto have duly executed this Agreement as a binding contract as of the date first above
written.

 

	COMPANY	 	EXECUTIVE
	 	 	 
	INHIBIKASE THERAPEUTICS, INC.	 	MILTON H. WERNER, PH.D.
	 	 	 
	 	 	
	By:	/s/ Lisa Evrén	 	/s/ Milton H. Werner
	 	Lisa Evrén, Director	 	 
	 	 	 	 
	 	 	 	 
	By:	/s/ Richard Fante	 	 
	 	Richard Fante, Director	 	 
	 	 	 	 
	 	 	 	 
	By:	/s/ Hilary Malone	 	 
	 	Hilary Malone, PhD, Director	 	 
	 	 	 	 
	 	 	 	 
	By:	/s/ Peter Mueller	 	 
	 	Peter Mueller, PhD, Director	 	 

 

    -18-

     

    

 

EXHIBIT
A

 

FORM
OF GENERAL RELEASE OF ALL CLAIMS

 

This General
Release of All Claims is made as of       ,
20          (“General Release”), by and between INHIBIKASE
THERAPEUTICS, INC. (the “Company”), and         (the
 “Executive”).

 

WHEREAS, the Company
and Executive are parties to an Employment Agreement dated as of, 20 (the “Employment Agreement”);

 

WHEREAS, the Company
wishes to terminate Executive’s employment with the Company without Cause or the Executive wishes to resign with Good Reason;

 

WHEREAS, defined terms
not defined in this General Release have the meanings given to them in the Employment Agreement;

 

WHEREAS, the execution
of this General Release is a condition precedent to the payment of certain payments or benefits following the Executive’s
termination, as set forth in Section 11 of the Employment Agreement;

 

WHEREAS, in consideration
for Executive’s signing of this General Release, as well as Executive’s continued compliance with the Employment Agreement,
including without limitation the non-competition and other restrictive covenants contained in Sections 15 through 17 of the Employment
Agreement, the Company will provide such payments or benefits to which the Executive may be entitled pursuant to Section 11 of
the Employment Agreement; and

 

WHEREAS, Executive
and the Company intend that this General Release shall be in full satisfaction of the obligations described in Section 11(f) of
the Employment Agreement owed by Executive to the Company.

 

NOW, THEREFORE, in
consideration of the promises and the mutual covenants and agreements herein contained, the Company and Executive agree as follows:

 

1.                 
Executive, for himself or herself, Executive’s spouse, heirs, administrators, children, representatives, executors,
successors, assigns, and all other persons claiming through Executive, if any (collectively, “Releasers”), does
hereby release, waive, and forever discharge the Company and each of its respective agents, subsidiaries, parents, affiliates,
related organizations, members, partners, shareholders, employees, officers, directors, attorneys, successors, and assigns (collectively,
the “Releasees”) from, and does fully waive any obligations of Releasees to Releasers for, any and all liability,
actions, charges, causes of action, demands, damages, or claims for relief, remuneration, sums of money, accounts or expenses (including
attorneys’ fees and costs) of any kind whatsoever, whether known or unknown or contingent or absolute, which heretofore has
been or which hereafter may be suffered or sustained, directly or indirectly, by Releasers in consequence of, arising out of, or
in any way relating to: (a) Executive’s employment with the Company or any of its subsidiaries or affiliates; (b) the termination
of Executive’s employment with the Company and any of its subsidiaries or affiliates; (c) the Employment Agreement; or (d)
any events occurring on or prior to the date of this General Release. The foregoing release and discharge, waiver and covenant
not to sue includes, but is not limited to, all claims and any obligations or causes of action arising from such claims, under
common law including wrongful or retaliatory discharge, breach of contract (including but not limited to any claims under the Employment
Agreement and any claims under any equity incentive arrangements between Executive, on the one hand, and the Company or any of
its subsidiaries or affiliates, on the other hand) and any action arising in tort including libel, slander, defamation or intentional
infliction of emotional distress, and claims under any federal, state or local statute including the Age Discrimination in Employment
Act (“ADEA”), Title VII of the Civil Rights Act of 1964 (“Title VII”), the Civil Rights Act
of 1866 and 1871 (42 U.S.C. § 1981), the National Labor Relations Act, the Fair Labor Standards Act, the Executive Retirement
Income Security Act, the Americans with Disabilities Act of 1990 (“ADA”), the Rehabilitation Act of 1973, the
discrimination or employment laws of any state or municipality, and/or any claims under any express or implied contract which Releasers
may claim existed with Releasees. This also includes a release of any claims for wrongful discharge and all claims for alleged
physical or personal injury, emotional distress relating to or arising out of Executive’s employment with the Company or
any of its subsidiaries or affiliates or the termination of that employment; and any claims under the Worker Adjustment and Retraining
Notification Act or any similar law, which requires, among other things, that advance notice be given of certain work force reductions.
This release and waiver does not apply to: (i) any right to indemnification now existing under the Company’s governing documents;
(ii) any rights to the receipt of Executive benefits under any Executive benefit plan which vested on or prior to the date of this
General Release; (iii) the right to receive certain payments or benefits under Section 11 of the Employment Agreement; and (iv)
the right to continuation health coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act.

 

    -19-

     

    

 

2.                 
Excluded from this General Release and waiver are any claims which cannot be waived by law, including but not limited to
the right to participate in an investigation conducted by certain government agencies. Executive does, however, waive Executive’s
right to any monetary recovery should any agency (such as the Equal Employment Opportunity Commission) pursue any claims on Executive’s
behalf. Executive represents and warrants that Executive has not filed any complaint, charge, or lawsuit against the Releasees
with any government agency or any court.

 

3.                 
Executive agrees never to seek personal recovery from Releasees in any forum for any claim covered by the above waiver and
release language. If Executive violates this General Release by suing Releasees, Executive shall be liable to the Releasees for
their reasonable attorneys’ fees and other litigation costs incurred in defending against such a suit and Executive shall
reimburse the Releasees for their costs and expenses. Nothing in this General Release is intended to reflect any party’s
belief that Executive’s waiver of claims under ADEA is invalid or unenforceable, it being the intent of the parties that
such claims are waived.

 

4.                 
To the extent, if any, that Executive has rights in any invention, improvement, discovery, process, program, product or
system developed by Executive during his or her employment with the Company, Executive hereby irrevocably transfers, assigns and
conveys such rights to the Company and agrees that the Company shall be and remain the sole and exclusive owner of all right, title
and interest in and to any such invention, improvement, discovery, process, program, product or system, including, but not limited
to, all patent, copyright, trade secret and other proprietary rights therein that may be secured in any place under laws now or
hereinafter in effect.

 

    -20-

     

    

 

5.                 
Executive agrees that neither this General Release, nor the furnishing of the consideration for this General Release, shall
be deemed or construed at any time to be an admission by the Company, any Releasees or Executive of any improper or unlawful conduct.

 

6.                 
Executive acknowledges and recites that:

 

(a)              
Executive has executed this General Release knowingly and voluntarily;

 

(b)              
Executive has read and understands this General Release in its entirety;

 

(c)              
Executive has been advised and directed orally and in writing (and this subparagraph (c) constitutes such written direction)
to seek legal counsel and any other advice Executive wishes with respect to the terms of this General Release before executing
it;

 

(d)              
By execution of this General Release, Executive expressly waives any and all claims relating to age discrimination and disability
or handicap discrimination and releases any rights he may have under Title VII, ADEA, the ADA, and/or any State or local laws;

 

(e)              
Executive hereby acknowledges that the waiver of his or her rights and/or claims existing under Title VII, ADEA and ADA
and/or any State or local laws is in consideration for payments or benefits to which the Executive is entitled under Section 11of
the Employment Agreement;

 

(f)               
Executive’s execution of this General Release has not been forced by any Executive or agent of the Company, and Executive
has had an opportunity to negotiate about the terms of this General Release; and

 

(g)              
Executive has been offered twenty-one (21) calendar days after receipt of this General Release to consider its terms before
executing it.I

 

7.                 
This General Release shall be governed by the internal laws (and not the choice of laws) of the Commonwealth of Massachusetts,
except for the application of pre-emptive Federal law.

 

8.                 
Executive shall have seven (7) days from the date Executive executes this General Release to revoke Executive’s waiver
of any ADEA claims by providing written notice of the revocation to the Company. In the event that Executive revokes this General
Release, the Company shall have no obligation to make any payments or benefits under Section 11 of the Employment Agreement that
were expressly conditioned on the execution of this release.

 

9.                 
Nothing in this General Release shall relieve Executive of his or her obligations under Sections 15 (Non-Competition), 16
(Non-Solicitation), or 17 (Confidentiality) of the Employment Agreement and Executive hereby agrees to comply with his or her obligations
as set forth in Sections 15, 16, and 17 of the Employment Agreement.

 

 

 

I
In the event Company determines that Employee’s termination constitutes “an exit incentive or other employment termination
program offered to a group or class of employees” under the ADEA, Company will provide Employee with: (1) 45 days to consider
the General Release; and (2) the disclosure schedules required for an effective release under the ADEA.

 

    -21-

     

    

 

10.             
If this General Release is found to be invalid or unenforceable in any way, the Executive shall execute and deliver to the
Company a revised release which will effectuate Executive’s intention to release the Releasees, as set forth herein, to the
maximum extent permitted by law.

 

PLEASE
READ THIS AGREEMENT CAREFULLY. IT CONTAINS A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS.

 

	Date:	 	 	 
	 	 	Executive

 

    -22-

     

    

 

EXHIBIT
B

 

EXCLUDED
PROPERTY FROM INTELLECTUAL PROPERTY ASSIGNMENT

 

    -23-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]